Stock CMND CLEARMIND MEDICINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Clearmind Medicine Inc.

Equities

CMND

CA1850534027

Delayed Nasdaq
Other stock markets
 10:28:19 2024-05-17 am EDT 		5-day change 1st Jan Change
1.3 USD +0.74% Intraday chart for Clearmind Medicine Inc. -7.86% -54.09%
May. 10 Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product CI
May. 07 Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
AQ
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
AQ
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
CI
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
AQ
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
CI
Clearmind Applies to Cease Being a Reporting Issuer in Canada
AQ
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
AQ
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
AQ
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
CI
Clearmind Medicine CEO Issues Letter to Shareholders
AQ
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression
CI
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
AQ
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration
CI
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K
PU
Clearmind Medicine Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024
CI
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
PR
Clearmind Medicine : Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board
GL
Clearmind Medicine : to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMND Stock
  4. News Clearmind Medicine Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW